News & events

News & events

Filter by:
  • Management TeamNews

VarmX recognised with two prestigious industry award nominations

Nominated for the 2026 Prix Galien USA “Best Startup” Award, and shortlisted with partner CSL for “Deal of the Year”...

  • News

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgery

First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking...

  • News

First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Bypassing Agent, VMX-C001

VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of...
  • News

VarmX awarded funding from the EIC Accelerator

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has been awarded up...
  • News

VarmX to Present New Data on Lead Compound, VMX-C001, at the ISTH 2021 Virtual Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new...
  • News

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • News

VarmX appoints Dr. Gerard Short as Chief Medical Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • Scientific publications

VMX-C001 is a Bypassing Agent for FXa-inhibiting DOACs and Displays a Favorable Pharmacokinetic and Pharmacodynamic Profile

Reversal of anticoagulation is important for safe usage of oral factor (F)Xa-inhibiting direct oral anticoagulants (FXa-DOACs).

...
  • News

VarmX raises € 32 million series B financing

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion...
  • News

VarmX raises € 12.5 million to develop VMX-COO1

VarmX, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, today announced...
  • News

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio